Christof von Kalle, MD

Director, National Center for Tumor Diseases (NCT) Heidelberg
Head, Department Translational Oncology, German Cancer Research Center (DKFZ)

Im Otto Meyerhof-Zentrum
Im Neuenheimer Feld 350
69120 Heidelberg
Germany

+49 6221 56 6991 (phone)
+49 6221 56 6930 (fax)
christof.kalle@nct-heidelberg.de

DOB: 6.3.1962

SCIENTIFIC VITA:

2005–pres	Director, National Center of Tumor Diseases (NCT) at the University Hospital Heidelberg and the German Cancer Research Center (DKFZ), Heidelberg, Germany
2005–pres	Tenured Full Professor and Chairman, Division of Translational Oncology, NCT
2005–pres	Chair, Department of Translation Oncology, DKFZ Heidelberg, Germany
2005–pres	Adjunct Professor of Pediatrics, Cincinnati Children's Hospital Medical Center, Div of Experimental Hematology, Cincinnati, OH, USA (Prof. Dr. David Williams).
2004–2005	Tenured Associate Professor of Internal Medicine, University of Freiburg, Germany
2002–2005	Program Leader "Gene and Molecular Therapy" Cincinnati Children's Hospital Medical Center, Div of Experimental Hematology, Cincinnati, OH, USA (Prof. Dr. David Williams).
2000–2005	Group Leader, Section of Hematopoiesis and Gene Transfer, Institute for Molecular Medicine, Freiburg University, Germany.
1996–2005	Senior Clinical Investigator, Gene Therapy Program, and Senior Medical Staff Fellow, Department of Internal Medicine, Freiburg University Medical School, Germany
1995–1996	Clinical Investigator and Senior Resident, Department of Internal Medicine, University of Cologne Medical School, Germany.
1992–1994	Associate in Clinical Research, Program of Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
1991	Medical PhD Degree
1989–1991	Post-doctoral Research Fellow and Clinical Junior Resident, Department of Internal Medicine, University of Cologne Medical School, Germany.
1988	Subinternship, Albert Einstein Medical School, New York, USA, Sloan Kettering Cancer Center and Cornell University Medical Center, New York, USA
1981–1987	MD, Cologne University Medical School

AWARDS:

2005	Langen Research Award, Paul-Ehrlich-Institute, Langen, Germany
2004	Elected, American Society of Clinical Investigation (ASCI)
2003	Young Investigator Award, American Society of Gene Therapy (ASGT)
1999–2006	15 Travel and Best Presentation Awards from ESGT, ASH and ASGT (Sen. Author)
1999	van Bekkum Award, European Group for Blood and Marrow Transplantation (EBMT)
1998	Best Presentation Award, German Society of Hematology/Oncology (DGHO)
1992–1994	Research Fellowship, German Research Foundation (DFG)
1982–1987	Scholarship, German Study Foundation (Top 1% of Graduates)

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS:

American Association for the Advancement of Science (AAAS)
American Association for Cancer Research (AACR)
American Society for Cell Biology (ASCB)
American Society for Clinical Investigation (ASCI)
American Society of Clinical Oncology (ASCO)
American Society of Gene Therapy (ASGT)
American Society of Hematology (ASH)
International Society for Stem Cell Research (ISSCR)
International Society for Experimental Hematology (ISEH)

FIELDS OF INTEREST:

Haematology and Oncology; short and long term hematopoiesis, preclinical and clinical cellular, molecular and gene therapy for cancer and inherited diseases, retrovirology

FUNDED PROJECTS:

EC	"Persisting transgenesis" (PERSIST), group application to the European Community, 7th framework program, work package leader, 2009-2012
Helmholtz Soc.	"Translational Medicine: Translating Immunotherapy into Medicine of the Future", Helmholtz-Alliance group application, Work package participant; 2008–2012.
EC	CLINIGENE: "European Network for the advancement of clinical gene transfer and therapy", Contractor in the Network of Excellence of the European Community, 6th Framework Program
BMBF	TreatID "Treatment of severe immunodeficiencies with gene modified stem cells"
Dt. Krebshilfe	"The human blood stemcell compartment in the nude NOD/SCID-ß2M-/- mouse-xenotransplantation model in calm, at stress and under constitutive expression of MDS/EVI1 and PRDM16"
DFG	"Stability, integration properties and vertical transmission of integrase deficient lentiviral vectors and their innovative uses in hematopoietic cells (SPP1230)"
DFG:	"Stem cell transplantation and immunomodulation – molecular therapy models in pediatrics"
EC	"Concerted safety and efficiency evaluation of retroviral transgenesis for gene therapy of inherited diseases (Consert)", group application to the European Community
NIH	"Vector Insertion and Mutagenesis in Human Hematopoiesis." R01 Application to HP (Hematopoiesis) Study Section NHLB, Principal Investigator
DFG	"Molecular detection of stem cell plasticity"
Dt. Krebshilfe	"Human short-term repopulating blood stem cells in a preclinical xenotransplantation model"
EC:	"Gene therapy of hematopoietic stem cells for inherited diseases" (INHERINET), group application to the European Community
DFG	"Lentiviral gene therapy of human mucopolysaccharidosis VI"
DFG	"Clonal analysis of human hematopoietic stem cells"
BMBF	"Retroviral gene therapy of human hematopoietic stem cells"
DFG	"Retroviral gene transfer into human hematopoietic stem cells"
BMBF:	"Relapse after autologous transplantation: genetic marking of stem cells for the analysis of clonality and origin of relapse"

PUBLICATIONS (Selection)

1. Eckenberg R, Gabriel R, Paruzynski A, Bartholomae CC, Nowrouzi A, Wang W, Schwarzwaelder K, Arens A, Kirsten R, Deichmann A, Ball CR, Howe SJ, Recchia A, Cattoglio C, Balaggan KS, Yáñez-Muñoz RL, Ali RR, Mavilio F, Gaspar HB, Thrasher AJ, Glimm H, **von Kalle C**, Saurin W, Schmidt M. Comprehensive Genomic Access To Viral Integration Sites in Clinical Gene Therapy, Nature Medicine. 2009, in press

2. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, Doglioni C, Di Serio C, **von Kalle C**, Naldini L. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009 Apr;119(4):964-75.

3. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, **von Kalle C**, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine. 2009 Mar;15(3):285-92.

4. Schmidt M, Schwarzwaelder K,, Bartholomae C., Zaoui K., Ball C., Pilz I., Braun S., Glimm H., **von Kalle C.** High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR) Nature Methods**,** 2007, 4(12), 1051-1057.

5. Deichmann A, Hacein-Bey Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm H, Gyapay G, Prum B, Fraser CC, Fischer N, Schwarzwaelder K, Siegler M, de Ridder D, Pike-Overzet K, Howe SJ, Thrasher AJ, Wagemaker G, Abel U, Staal F, Delabesse E, Villeval J, Aronow B, Hue C, Prinz C, Wissler M, Klanke C, Weissenbach J, Alexander I, Fischer A, **von Kalle C* (corr)** and Cavazzana-Calvo M. Vector Integration is Non-Random, Clustered and Influences the Fate of Lymphopoiesis in SCID-X1 Gene Therapy. J Clin Invest. 2007:117(8): 2225-32.

6. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi LS, Benedicenti F, Ambrosi A, Di Serio C, Dogliosi C, **von Kalle C**, Naldini L. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nature Biotech. 2006;24(6):687–96.

7. Woods NB, Bottero V; Schmidt M, **von Kalle C**, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature. 2006 Apr 27;440(7088):1123.
Woods NB, Bottero V, Schmidt M, **von Kalle C**, Verma IM. Gene therapy: Is IL2RG oncogenic in T-cell development?: X-SCID transgene leukaemogenicity (reply). Nature**.** 2006;443(7109):E6–E7.

8. Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, **von Kalle C (co-corresponding and co-senior author)**, Seger R, Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1/EVI1, PRDM16 or SETBP1. Nature Medicine. 2006;12(4):401-9.

9. Glimm H, Schmidt M, Fischer M, Schwarzwaelder K, Wissler M, Klingenberg S, Prinz C, Waller CF, Lange W, Eaves CJ, **von Kalle C**. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood. 2005;106(3):893–8.

10. Hacein-Bey-Abina S*, **Von Kalle C***, **(cofirst author*)** Schmidt M*, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-9.

11. Schmidt M, Carbonaro D, Speckmann C, Wissler M, Bohnsack J, Elder M, Aronow B, Nolta JA, Kohn DB and **von Kalle C**. Clonality Analysis after Retroviral-Mediated Gene Transfer To CD34+ Cells from the Cord Blood of ADA-Deficient SCID Neonates. Nature Medicine. 2003;9(4):463-8.

12. Hacein-Bey-Abina S, **von Kalle C**, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency**.** N Engl J Med. 2003;348(3):255-6.